Organization
Peking University Cancer Hospital and Institute, Beijing, China
5 abstracts
Abstract
Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.Org: Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Beijing Cancer Hospital, Beijing, China, Department of Gastrointestinal Oncology, Beijing Cancer Hospital, Beijing, China, Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.Org: Peking University Cancer Hospital and Institute, Beijing, China, The First Affiliated Hospital of Henan University of Science and Technology, Shanghai East Hospital, Zhongnan Hospital of Wuhan University, The First Affiliated Hospital of Xinxiang Medical University,
Abstract
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Second Department of Thoracic Tumors, Peking University Cancer Hospital, Department of Medical Oncology, Harbin Medical University Cancer Hospital, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology,
Abstract
Deep learning-derived spatial organization features on histopathology images to predict prognosis in patients with colorectal liver metastasis, after hepatectomy.Org: Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China, Peking University Cancer Hospital and Institute, Beijing, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China, The Eastern Hospital of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Tianjin Medical University Cancer Institiute and Hospital, Tianjin, China, Department of VIP Medical Services, Shanxi Province Cancer Hospital, Shanxi, China, Fujian Cancer Hospital, Fuzhou, China, Jilin Cancer Hospital, Changchun, China, Affiliated Cancer Hospital of Harbin Medical University, Harbin, China, Meizhou People's Hospital, Meizhou, China, Hunan Cancer hospital, Changsha, China, Linfen City People's Hospital, Linfen, China, Sichuan Provincial People's Hospital, Chengdu, China, Yunnan Cancer Hospital, Kunming, China, Henan Cancer Hospital, Zhengzhou, China, The First Affiliated Hospital of Xiamen University, Xiamen, China, Gansu Provincial Cancer Hospital, Lanzhou, China, Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China, Changzhi People's Hospital, Changzhi, China, CSPC ZhongQi Pharmaceutical Technology Co., Ltd, Shijiazhuang, China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China, Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China,
Abstract
Efficacy and safety of high dose twice-daily thoracic radiotherapy versus standard dose for limited stage small-cell lung cancer: A multicentre, open-label randomised, phase 3 trial.Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China, The First Affiliated Hospital of Air Force Military Medical University (Xijing Hospital), Xian, China, Anyang Cancer Hospital, Anyang, China, Beijing University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China,